This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Renal Cell Carcinoma
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
-
University of Arizona Cancer Center, Tucson, Arizona, United States, 85719
University of California San Diego Moores Cancer Center, La Jolla, California, United States, 92093
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States, 80124
HealthPartners Cancer Research Center, Saint Paul, Minnesota, United States, 55101
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106
Cleveland Clinic, Cleveland, Ohio, United States, 44195
Providence Cancer Institute, Portland, Oregon, United States, 97213
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
HiberCell, Inc.,
2027-11